Likewise, the intellectual property protections might have established a 12-year monopoly on the data that US pharmaceutical and biotechnology companies compile on new drugs (particularly biologics), thereby impeding competition from lower-cost generic versions. In the end, these companies did not get all they wanted; while the TPP in some ways gives their intellectual property more protection than they had before, it assures protection of their data for only 5-8 years.
类似地，知识产权保护已经为美国制药和生物科技公司建立了12年的新药（特别是生物制药）数据垄断，从而阻止来自成本更低的仿制药的竞争。最后，这些公司没有得到想要的一切；尽管TPP以某种方式给了它们比以前更多的知识产权保护，但对于它们的新药数据，保护期只有5—8年。